Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugs
- PMID: 17803346
- DOI: 10.2165/00044011-200727100-00006
Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugs
Abstract
Objective: Obese patients often present with multiple co-morbid conditions, including hypertension, which are associated with an increased cardiovascular (CV) risk. We aimed to assess the risk factor profiles of primary-care patients with obesity and hypertension in order to estimate their fatal CV risk in total and according to use of various antihypertensive drugs.
Methods: This was a post-hoc analysis of data from a recent observational study involving 72 479 hypertensive patients in 6989 general practices across Germany. Almost all patients (92.3%) were overweight or obese. The 10-year risk for fatal CV events was determined using the SCORE algorithm as published by the European Society of Cardiology.
Results: Overall, 68% of patients had one or more diseases or conditions in addition to obesity and hypertension. The 10-year fatal CV risk was lowest in the youngest normal weight group (1.7%), and highest in the oldest obese group (26%). Men had a higher risk than women, and risk rose with increasing age. The risk factor profile appeared to differ between patients treated with various antihypertensive classes, e.g. angiotensin II type 1 receptor antagonists were associated with lower risk, diuretics with higher risk. There were moderate differences within drug classes.
Conclusions: According to this cross-sectional data, fatal CV risk is strongly increased in obese patients, especially in men and in older age groups. While there were strong associations between use of certain drugs and metabolic risk markers and overall fatal CV risk, the causality of these associations remains to be determined.
Similar articles
-
[Consumption of antihypertensive agents in obese patients: a cross-sectional study in a sample of 3,291 wage-earners in the Toulous region].Arch Mal Coeur Vaiss. 2000 Aug;93(8):925-9. Arch Mal Coeur Vaiss. 2000. PMID: 10989731 French.
-
[Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Aug;25(8):710-4. Zhonghua Liu Xing Bing Xue Za Zhi. 2004. PMID: 15555399 Chinese.
-
The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.Drugs Aging. 2006;23(2):131-55. doi: 10.2165/00002512-200623020-00004. Drugs Aging. 2006. PMID: 16536636 Review.
-
HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.High Blood Press Cardiovasc Prev. 2015 Jun;22(2):165-72. doi: 10.1007/s40292-015-0091-6. Epub 2015 Apr 22. High Blood Press Cardiovasc Prev. 2015. PMID: 25900022
-
The Role of Beta-Blockers in the Treatment of Hypertension.Adv Exp Med Biol. 2017;956:149-166. doi: 10.1007/5584_2016_36. Adv Exp Med Biol. 2017. PMID: 27957711 Review.
Cited by
-
Local adipose tissue renin-angiotensin system.Curr Hypertens Rep. 2008 Apr;10(2):93-8. doi: 10.1007/s11906-008-0019-9. Curr Hypertens Rep. 2008. PMID: 18474174 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical